NCT03833089View on ClinicalTrials.gov

Targeted Potassium Levels for Prevention of ICD Therapy

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

May 9, 2025

Study Completion Date

April 1, 2035

Conditions
Ventricular Arrhythmias and Cardiac ArrestImplantable Defibrillator UserHypokalemiaHyperkalemiaVentricular TachycardiaAtrial Fibrillation
Interventions
COMBINATION_PRODUCT

Targeted serum potassium level

In the following order, following advices end prescriptions will be provided: 1) Potassium rich dietary advice, 2) Mineralocorticoid receptor antagonists, 3) Potassium supplementation,

Trial Locations (3)

2100

Rigshospitalet, Copenhagen

2900

Gentofte University Hospital, Gentofte Municipality

4000

Roskilde University Hospital, Roskilde

All Listed Sponsors
collaborator

Herlev and Gentofte Hospital

OTHER

lead

Rigshospitalet, Denmark

OTHER

NCT03833089 - Targeted Potassium Levels for Prevention of ICD Therapy | Biotech Hunter | Biotech Hunter